In vivo Imaging of Antioxidant Effects on NF-κB Activity in Reporter Mice

  • Ingvild Paur
  • Harald Carlsen
  • Rune BlomhoffEmail author
Part of the Oxidative Stress in Applied Basic Research and Clinical Practice book series (OXISTRESS)


In this chapter, we describe how we have utilized transgenic reporter mice and cell lines to investigate how phytochemicals/antioxidants and dietary plants can modulate NF-κB transcription factor activity. Several dietary plants are found to be potent modulators of NF-κB activity in vivo. Even though these dietary plants are rich in antioxidants/phytochemicals, the contribution of antioxidant properties per se, to these effects on NF-κB remain uncertain. Also, the relationship and interactions between antioxidants/ROS and the NF-κB signalling pathway is complex and still not fully elicidated. In line with this discussion, we find different dietary plants to be able to both inhibit and induce NF-κB activity, and we speculate that both might contribute to the preventive effects of diets rich in plant-based foods towards chronic diseases.


In vivo imaging NF-κB Nutrition Phytochemicals ROS 


  1. 1.
    Hotamisligil, G.S. (2006) Inflammation and metabolic disorders Nature 444, 860–867.Google Scholar
  2. 2.
    Mantovani, A., Allavena, P., Sica, A. et al. (2008) Cancer-related inflammation Nature 454, 436–444.Google Scholar
  3. 3.
    Libby, P. (2002) Inflammation in atherosclerosis Nature 420, 868–874.Google Scholar
  4. 4.
    Pikarsky, E., Porat, R.M., Stein, I. et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer Nature 431, 461–466.Google Scholar
  5. 5.
    Luo, J.L., Maeda,S., Hsu, L.C. et al. (2004) Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression Cancer Cell 6, 297–305.Google Scholar
  6. 6.
    Ekbom, A. (1998) Risk of cancer in ulcerative colitis J Gastrointest Surg 2, 312–313.Google Scholar
  7. 7.
    Roder, D.M. (2002) The epidemiology of gastric cancer Gastric Cancer 5 Suppl 1, 5–11.Google Scholar
  8. 8.
    Bosetti, C., Gallus,S., and La, V.C. (2006) Aspirin and cancer risk: an updated quantitative review to 2005 Cancer Causes Control 17, 871–888.Google Scholar
  9. 9.
    Witz, I.P. (2008) Yin-yang activities and vicious cycles in the tumor microenvironment Cancer Res 68, 9–13.Google Scholar
  10. 10.
    Hagemann, T., Biswas, S.K., Lawrence, T. et al. (2009) Regulation of macrophage function in tumors: the multifaceted role of NF-{kappa}B Blood 113, 3139–3146.Google Scholar
  11. 11.
    Lin, E.Y., Nguyen, A.V., Russell, R.G. et al. (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy J Exp Med 193, 727–740.Google Scholar
  12. 12.
    Balkwill, F. and Mantovani, A. (2001) Inflammation and cancer: back to Virchow? Lancet 357, 539–545.Google Scholar
  13. 13.
    Balkwill, F. (2009) Tumour necrosis factor and cancer Nat Rev Cancer 9, 361–371.Google Scholar
  14. 14.
    Maeda, S., Kamata, H., Luo, J.L. et al. (2005) IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis Cell 121, 977–990.Google Scholar
  15. 15.
    Greten, F.R., Eckmann, L., Greten, T.F. et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer Cell 118, 285–296.Google Scholar
  16. 16.
    Karin, M., Yamamoto, Y., and Wang, Q.M. (2004) The IKK NF-kappaB system: a treasure trove for drug development Nat Rev Drug Discov 3, 17–26.Google Scholar
  17. 17.
    Sen, R. and Baltimore, D. (1986) Multiple nuclear factors interact with the immunoglobulin enhancer sequences Cell 46, 705–716.Google Scholar
  18. 18.
    Valen, G., Yan, Z.Q., and Hansson, G.K. (2001) Nuclear factor kappa-B and the heart J Am Coll Cardiol 38, 307–314.Google Scholar
  19. 19.
    Mattson, M.P. and Camandola, S. (2001) NF-kappaB in neuronal plasticity and neurodegenerative disorders J Clin Invest 107, 247–254.Google Scholar
  20. 20.
    Feldmann, M., Andreakos, E., Smith, C. et al. (2002) Is NF-kappaB a useful therapeutic target in rheumatoid arthritis? Ann Rheum Dis 61 Suppl 2, ii13–ii18.Google Scholar
  21. 21.
    Christman, J.W., Sadikot, R.T., and Blackwell, T.S. (2000) The role of nuclear factor-kappa B in pulmonary diseases Chest 117, 1482–1487.Google Scholar
  22. 22.
    Neurath, M.F., Becker, C., and Barbulescu, K. (1998) Role of NF-kappaB in immune and inflammatory responses in the gut Gut 43, 856–860.Google Scholar
  23. 23.
    Karin, M., Cao,Y., Greten, F.R. et al. (2002) NF-kappaB in cancer: from innocent bystander to major culprit Nat Rev Cancer 2, 301–310.Google Scholar
  24. 24.
    Greten, F.R. and Karin, M. (2004) The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer Cancer Lett 206, 193–199.Google Scholar
  25. 25.
    Chen, L.F. and Greene, W.C. (2004) Shaping the nuclear action of NF-kappaB Nat Rev Mol Cell Biol 5, 392–401.Google Scholar
  26. 26.
    Natoli, G., Saccani, S., Bosisio, D. et al. (2005) Interactions of NF-kappaB with chromatin: the art of being at the right place at the right time Nat Immunol 6, 439–445.Google Scholar
  27. 27.
    Yang, F., Tang, E., Guan, K. et al. (2003) IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide J Immunol 170, 5630–5635.Google Scholar
  28. 28.
    Pahl, H.L. (1999) Activators and target genes of Rel/NF-kappaB transcription factors Oncogene 18, 6853–6866.Google Scholar
  29. 29.
    Hoffmann, A., Levchenko, A., Scott, M.L. et al. (2002) The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation Science 298, 1241–1245.Google Scholar
  30. 30.
    Bonizzi, G. and Karin, M. (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity Trends Immunol 25, 280–288.Google Scholar
  31. 31.
    Lawrence, T., Bebien, M., Liu, G.Y. et al. (2005) IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation Nature 434, 1138–1143.Google Scholar
  32. 32.
    Senftleben, U., Cao, Y., Xiao, G. et al. (2001) Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway Science 293, 1495–1499.Google Scholar
  33. 33.
    Ghosh, S. and Karin, M. (2002) Missing pieces in the NF-kappaB puzzle Cell 109 Suppl, S81–S96.Google Scholar
  34. 34.
    Gilmore, T.D. and Herscovitch, M. (2006) Inhibitors of NF-kappaB signaling: 785 and counting Oncogene 25, 6887–6899.Google Scholar
  35. 35.
    Gilmore, T.D. (2009) www nf-kb org
  36. 36.
    Beg, A.A. and Baltimore, D. (1996) An essential role for NF-kappaB in preventing TNF-alpha-induced cell death Science 274, 782–784.Google Scholar
  37. 37.
    Li, Q., Van,A.D., Mercurio, F. et al. (1999) Severe liver degeneration in mice lacking the IkappaB kinase 2 gene Science 284, 321–325.Google Scholar
  38. 38.
    Rudolph, D., Yeh, W.C., Wakeham, A. et al. (2000) Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice Genes Dev 14, 854–862.Google Scholar
  39. 39.
    Hall, G., Hasday, J.D., and Rogers, T.B. (2006) Regulating the regulator: NF-kappaB signaling in heart J Mol Cell Cardiol 41, 580–591.Google Scholar
  40. 40.
    Tillmanns, J., Carlsen, H., Blomhoff, R. et al. (2006) Caught in the act: in vivo molecular imaging of the transcription factor NF-kappaB after myocardial infarction Biochem Biophys Res Commun 342, 773–774.Google Scholar
  41. 41.
    Armani, A. and Becker, R.C. (2005) The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part I Am Heart J 149, 971–976.Google Scholar
  42. 42.
    Ridker, P.M., Rifai, N., Stampfer, M.J. et al. (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men Circulation 101, 1767–1772.Google Scholar
  43. 43.
    Han, Y., Runge, M.S., and Brasier, A.R. (1999) Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors Circ Res 84, 695–703.Google Scholar
  44. 44.
    Damas, J.K. and Aukrust, P. (2006) Systemic markers of inflammation–are they useful predictive tools in coronary artery disease? Scand Cardiovasc J 40, 262–266.Google Scholar
  45. 45.
    Halvorsen, B., Otterdal, K., Dahl,T.B. et al. (2008) Atherosclerotic plaque stability--what determines the fate of a plaque? Prog Cardiovasc Dis 51, 183–194.Google Scholar
  46. 46.
    Agrawal, A., Samols, D., and Kushner, I. (2003) Transcription factor c-Rel enhances C-reactive protein expression by facilitating the binding of C/EBPbeta to the promoter Mol Immunol 40, 373–380.Google Scholar
  47. 47.
    Libermann, T.A. and Baltimore, D. (1990) Activation of interleukin-6 gene expression through the NF-kappa B transcription factor Mol Cell Biol 10, 2327–2334.Google Scholar
  48. 48.
    Son, Y.H., Jeong, Y.T., Lee, K.A. et al. (2008) Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells J Cardiovasc Pharmacol 51, 71–77.Google Scholar
  49. 49.
    Van de, S.A., Caldenhoven, E., Stade, B.G. et al. (1994) 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter J Biol Chem 269, 6185–6192.Google Scholar
  50. 50.
    Iademarco, M.F., McQuillan, J.J., Rosen, G.D. et al. (1992) Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1) J Biol Chem 267, 16323–16329.Google Scholar
  51. 51.
    Sica, A., Dorman,L., Viggiano, V. et al. (1997) Interaction of NF-kappaB and NFAT with the interferon-gamma promoter J Biol Chem 272, 30412–30420.Google Scholar
  52. 52.
    Sica, A., Tan, T.H., Rice, N. et al. (1992) The c-rel protooncogene product c-Rel but not NF-kappa B binds to the intronic region of the human interferon-gamma gene at a site related to an interferon-stimulable response element Proc Natl Acad Sci USA 89, 1740–1744.Google Scholar
  53. 53.
    Vincenti, M.P., Coon, C.I., and Brinckerhoff, C.E. (1998) Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts Arthritis Rheum 41, 1987–1994.Google Scholar
  54. 54.
    He, C. (1996) Molecular mechanism of transcriptional activation of human gelatinase B by proximal promoter Cancer Lett 106, 185–191.Google Scholar
  55. 55.
    Borghaei, R.C., Rawlings, P.L., Jr., Javadi, M. et al. (2004) NF-kappaB binds to a polymorphic repressor element in the MMP-3 promoter Biochem Biophys Res Commun 316, 182–188.Google Scholar
  56. 56.
    Karin, M. and Greten, F.R. (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression Nat Rev Immunol 5, 749–759.Google Scholar
  57. 57.
    Sun, S.C. and Xiao, G. (2003) Deregulation of NF-kappaB and its upstream kinases in cancer Cancer Metastasis Rev 22, 405–422.Google Scholar
  58. 58.
    Rayet, B. and Gelinas, C. (1999) Aberrant rel/nfkb genes and activity in human cancer Oncogene 18, 6938–6947.Google Scholar
  59. 59.
    Park, J.M., Greten, F.R., Wong, A. et al. (2005) Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis--CREB and NF-kappaB as key regulators Immunity 23, 319–329.Google Scholar
  60. 60.
    Hsu, L.C., Park, J.M., Zhang, K. et al. (2004) The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4 Nature 428, 341–345.Google Scholar
  61. 61.
    Colombo, M.P. and Mantovani, A. (2005) Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion Cancer Res 65, 9113–9116.Google Scholar
  62. 62.
    Hagemann, T., Lawrence, T., McNeish, I. et al. (2008) “Re-educating” tumor-associated macrophages by targeting NF-kappaB J Exp Med 205, 1261–1268.Google Scholar
  63. 63.
    Hagemann, T., Balkwill, F., and Lawrence, T. (2007) Inflammation and cancer: a double-edged sword Cancer Cell 12, 300–301.Google Scholar
  64. 64.
    Surh, Y.J. (2003) Cancer chemoprevention with dietary phytochemicals Nat Rev Cancer 3, 768–780.Google Scholar
  65. 65.
    Luo, J.L., Kamata, H., and Karin, M. (2005) IKK/NF-kappaB signaling: balancing life and death – a new approach to cancer therapy J Clin Invest 115, 2625–2632.Google Scholar
  66. 66.
    Jacobs, D.R., Jr. and Tapsell, L.C. (2007) Food, not nutrients, is the fundamental unit in nutrition Nutr Rev 65, 439–450.Google Scholar
  67. 67.
    Paur, I., Austenaa, L.M., and Blomhoff, R. (2008) Extracts of dietary plants are efficient modulators of nuclear factor kappa B Food Chem Toxicol 46, 1288–1297.Google Scholar
  68. 68.
    Contag, C.H., Contag, P.R., Mullins, J.I. et al. (1995) Photonic detection of bacterial pathogens in living hosts Mol Microbiol 18, 593–603.Google Scholar
  69. 69.
    Carlsen, H., Moskaug, J.O., Fromm, S.H. et al. (2002) In vivo imaging of NF-kappa B activity J Immunol 168, 1441–1446.Google Scholar
  70. 70.
    Chung, J.H., Bell,A.C., and Felsenfeld, G. (1997) Characterization of the chicken beta-globin insulator Proc Natl Acad Sci USA 94, 575–580.Google Scholar
  71. 71.
    Pikaart, M.J., Recillas-Targa, F., and Felsenfeld, G. (1998) Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators Genes Dev 12, 2852–2862.Google Scholar
  72. 72.
    Recillas-Targa, F., Pikaart, M.J., Burgess-Beusse, B. et al. (2002) Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities Proc Natl Acad Sci USA 99, 6883–6888.Google Scholar
  73. 73.
    Zangani, M., Carlsen, H., Kielland, A. et al. (2009) Tracking early autoimmune disease by bioluminescent imaging of NF-kappaB activation reveals pathology in multiple organ systems Am J Pathol 174, 1358–1367.Google Scholar
  74. 74.
    Alexander, G., Carlsen, H., and Blomhoff,R. (2006) Corneal NF-kappaB activity is necessary for the retention of transparency in the cornea of UV-B-exposed transgenic reporter mice Exp Eye Res 82, 700–709.Google Scholar
  75. 75.
    Austenaa, L.M., Carlsen, H., Hollung, K. et al. (2009) Retinoic acid dampens LPS-induced NF-kappaB activity: results from human monoblasts and in vivo imaging of NF-kappaB reporter mice J Nutr Biochem 20, 726–734.Google Scholar
  76. 76.
    Carlsen, H., Haugen, F., Zadelaar, S. et al. (2009) Diet-induced obesity increases NF-kappaB signaling in reporter mice Genes Nutr 4, 215–222.Google Scholar
  77. 77.
    Dohlen, G., Carlsen, H., Blomhoff, R. et al. (2005) Reoxygenation of hypoxic mice with 100% oxygen induces brain nuclear factor-kappa B Pediatr Res 58, 941–945.Google Scholar
  78. 78.
    Notebaert, S., Carlsen, H., Janssen, D. et al. (2008) In vivo imaging of NF-kappaB activity during Escherichia coli-induced mammary gland infection Cell Microbiol 10, 1249–1258.Google Scholar
  79. 79.
    Paur, I., Balstad, T.R., Kolberg, M. et al. (2010) Extract of oregano, coffee, thyme, clove, and walnuts inhibits NF-kappaB in monocytes and in transgenic reporter mice Cancer Prev Res (Phila Pa) 3, 653–663.Google Scholar
  80. 80.
    Balstad, T.R., Paur, I., Poulsen, M. et al. (2010) Apple, cherry and blackcurrant increases Nuclear Factor kappa B activation in liver of transgenic mice Nutr Cancer 62, 841–848.Google Scholar
  81. 81.
    Paur, I., Balstad, T.R., and Blomhoff, R. (2010) Degree of roasting is the main determinant of the effects of coffee on NF-kappaB and EpRE Free Radic Biol Med 48, 1218–1227.Google Scholar
  82. 82.
    Wang, T.T. (2002) beta-naphthoflavone, an inducer of xenobiotic metabolizing enzymes, inhibits firefly luciferase activity. Anal Biochem 304, 122–126.Google Scholar
  83. 83.
    Bakhtiarova, A., Taslimi,P., Elliman, S.J. et al. (2006) Resveratrol inhibits firefly luciferase Biochem Biophys Res Commun 351, 481–484.Google Scholar
  84. 84.
    Huang, C., Huang, Y., Li,J. et al. (2002) Inhibition of benzo(a)pyrene diol-epoxide-induced transactivation of activated protein 1 and nuclear factor kappaB by black raspberry extracts Cancer Res 62, 6857–6863.Google Scholar
  85. 85.
    Wang, S.Y., Feng, R., Bowman, L. et al. (2005) Antioxidant activity in lingonberries (Vaccinium vitis-idaea L.) and its inhibitory effect on activator protein-1, nuclear factor-kappaB, and mitogen-activated protein kinases activation J Agric Food Chem 53, 3156–3166.Google Scholar
  86. 86.
    Wang, S.Y., Feng, R., Lu, Y. et al. (2005) Inhibitory effect on activator protein-1, nuclear factor-kappaB, and cell transformation by extracts of strawberries (Fragaria x ananassa Duch.) J Agric Food Chem 53, 4187–4193.Google Scholar
  87. 87.
    Khan, N., Afaq, F., Kweon, M.H. et al. (2007) Oral Consumption of Pomegranate Fruit Extract Inhibits Growth and Progression of Primary Lung Tumors in Mice Cancer Res 67, 3475–3482.Google Scholar
  88. 88.
    Rettig, M.B., Heber,D., An, J. et al. (2008) Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism Mol Cancer Ther 7, 2662–2671.Google Scholar
  89. 89.
    Atalay, M., Gordillo, G., Roy, S. et al. (2003) Anti-angiogenic property of edible berry in a model of hemangioma FEBS Lett 544, 252–257.Google Scholar
  90. 90.
    Rajakangas, J., Misikangas, M., Paivarinta, E. et al. (2008) Chemoprevention by white currant is mediated by the reduction of nuclear beta-catenin and NF-kappaB levels in Min mice adenomas Eur J Nutr 47, 115–122.Google Scholar
  91. 91.
    Bukovska, A., Cikos, S., Juhas, S. et al. (2007) Effects of a combination of thyme and oregano essential oils on TNBS-induced colitis in mice Mediators Inflamm 2007, 23296–Google Scholar
  92. 92.
    Sasaki, K., Wada, K., Tanaka, Y. et al. (2005) Thyme (Thymus vulgaris L.) leaves and its constituents increase the activities of xenobiotic-metabolizing enzymes in mouse liver J Med Food 8, 184–189.Google Scholar
  93. 93.
    Lee, J., Jung, E., Kim, Y. et al. (2006) Rosmarinic acid as a downstream inhibitor of IKK-beta in TNF-alpha-induced upregulation of CCL11 and CCR3 Br J Pharmacol 148, 366–375.Google Scholar
  94. 94.
    Shan, B., Cai, Y.Z., Sun, M. et al. (2005) Antioxidant capacity of 26 spice extracts and characterization of their phenolic constituents J Agric Food Chem 53, 7749–7759.Google Scholar
  95. 95.
    Kim, S.H., Jun, C.D., Suk, K. et al. (2006) Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells Toxicol Sci 91, 123–131.Google Scholar
  96. 96.
    Chainy, G.B., Manna, S.K., Chaturvedi, M.M. et al. (2000) Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappaB, AP-1, JNK, MAPKK and apoptosis Oncogene 19, 2943–2950.Google Scholar
  97. 97.
    Aggarwal, B.B. and Shishodia,S. (2006) Molecular targets of dietary agents for prevention and therapy of cancer Biochem Pharmacol 71, 1397–1421.Google Scholar
  98. 98.
    Takada, Y., Bhardwaj,A., Potdar,P. et al. (2004) Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation Oncogene 23, 9247–9258.Google Scholar
  99. 99.
    Strimpakos, A.S. and Sharma, R.A. (2008) Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials Antioxid Redox Signal 10, 511–545.Google Scholar
  100. 100.
    Plummer, S.M., Holloway, K.A., Manson, M.M. et al. (1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex Oncogene 18, 6013–6020.Google Scholar
  101. 101.
    Yang, C.S., Sang,S., Lambert, J.D. et al. (2008) Bioavailability issues in studying the health effects of plant polyphenolic compounds Mol Nutr Food Res 52 Suppl 1, S139–S151.Google Scholar
  102. 102.
    Reyes-Gordillo, K., Segovia, J., Shibayama, M. et al. (2007) Curcumin protects against acute liver damage in the rat by inhibiting NF-[kappa]B, proinflammatory cytokines production and oxidative stress. Biochim Biophys Acta 1770, 989–996.Google Scholar
  103. 103.
    Farombi, E.O., Shrotriya, S., Na, H.K. et al. (2008) Curcumin attenuates dimethylnitrosamine-induced liver injury in rats through Nrf2-mediated induction of heme oxygenase-1 Food Chem Toxicol 46, 1279–1287.Google Scholar
  104. 104.
    Saaksjarvi, K., Knekt, P., Rissanen, H. et al. (2007) Prospective study of coffee consumption and risk of Parkinson’s disease Eur J Clin Nutr 62, 908–915.Google Scholar
  105. 105.
    Leitzmann, M.F., Willett, W.C., Rimm, E.B. et al. (1999) A prospective study of coffee consumption and the risk of symptomatic gallstone disease in men JAMA 281, 2106–2112.Google Scholar
  106. 106.
    Cornelis, M.C. and El Sohemy, A. (2007) Coffee caffeine and coronary heart disease. Curr Opin Lipidol 18, 13–19.Google Scholar
  107. 107.
    Ruhl, C.E. and Everhart, J.E. (2005) Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States Gastroenterology 129, 1928–1936.Google Scholar
  108. 108.
    Tverdal, A. and Skurtveit, S. (2003) Coffee intake and mortality from liver cirrhosis Ann Epidemiol 13, 419–423.Google Scholar
  109. 109.
    Larsson, S.C. and Wolk, A. (2007) Coffee consumption and risk of liver cancer: a meta-analysis Gastroenterology 132, 1740–1745.Google Scholar
  110. 110.
    Wakai, K., Kurozawa,Y., Shibata, A. et al. (2007) Liver cancer risk, coffee, and hepatitis C virus infection: a nested case-control study in Japan. Br J Cancer 97, 426–428.Google Scholar
  111. 111.
    van Dam, R.M. and Hu, F.B. (2005) Coffee consumption and risk of type 2 diabetes: a systematic review JAMA 294, 97–104.Google Scholar
  112. 112.
    Andersen, L.F., Jacobs, D.R., Jr., Carlsen, M.H. et al. (2006) Consumption of coffee is associated with reduced risk of death attributed to inflammatory and cardiovascular diseases in the Iowa Women’s Health Study Am J Clin Nutr 83, 1039–1046.Google Scholar
  113. 113.
    Somoza, V. (2005) Five years of research on health risks and benefits of Maillard reaction products: an update Mol Nutr Food Res 49, 663–672.Google Scholar
  114. 114.
    Esposito, F., Morisco,F., Verde, V. et al. (2003) Moderate coffee consumption increases plasma glutathione but not homocysteine in healthy subjects Aliment Pharmacol Ther 17, 595–601.Google Scholar
  115. 115.
    Huber, W.W., Prustomersky, S., Delbanco, E. et al. (2002) Enhancement of the chemoprotective enzymes glucuronosyl transferase and glutathione transferase in specific organs of the rat by the coffee components kahweol and cafestol Arch Toxicol 76, 209–217.Google Scholar
  116. 116.
    Chung, T.W., Moon, S.K., Chang, Y.C. et al. (2004) Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism FASEB J 18, 1670–1681.Google Scholar
  117. 117.
    Muscat, S., Pelka, J., Hegele, J. et al. (2007) Coffee and Maillard products activate NF-kappaB in macrophages via H2O2 production Mol Nutr Food Res 51, 525–535.Google Scholar
  118. 118.
    Ramos, S. (2008) Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways Mol Nutr Food Res 52, 507–526.Google Scholar
  119. 119.
    World Cancer Research Fund (2007) Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective.Google Scholar
  120. 120.
    Bieger, J., Cermak, R., Blank,R. et al. (2008) Tissue distribution of quercetin in pigs after long-term dietary supplementation J Nutr 138, 1417–1420.Google Scholar
  121. 121.
    Suganuma, M., Okabe, S., Oniyama, M. et al. (1998) Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue Carcinogenesis 19, 1771–1776.Google Scholar
  122. 122.
    Mullen, W., Graf, B.A., Caldwell, S.T. et al. (2002) Determination of flavonol metabolites in plasma and tissues of rats by HPLC-radiocounting and tandem mass spectrometry following oral ingestion of [2-(14)C]quercetin-4’-glucoside J Agric Food Chem 50, 6902–6909.Google Scholar
  123. 123.
    Vitrac, X., Desmouliere, A., Brouillaud, B. et al. (2003) Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration Life Sci 72, 2219–2233.Google Scholar
  124. 124.
    Manach, C., Williamson, G., Morand, C. et al. (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies Am J Clin Nutr 81, 230S–242S.Google Scholar
  125. 125.
    Xu, W., Hellerbrand, C., Kohler, U.A. et al. (2008) The Nrf2 transcription factor protects from toxin-induced liver injury and fibrosis Lab Invest 88, 1068–1078.Google Scholar
  126. 126.
    Ramos-Gomez, M., Kwak, M.K., Dolan, P.M. et al. (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice Proc Natl Acad Sci USA 98, 3410–3415.Google Scholar
  127. 127.
    Karin, M., Takahashi, T., Kapahi, P. et al. (2001) Oxidative stress and gene expression: the AP-1 and NF-kappaB connections Biofactors 15, 87–89.Google Scholar
  128. 128.
    Bowie, A. and O’Neill, L.A. (2000) Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries Biochem Pharmacol 59, 13–23.Google Scholar
  129. 129.
    Bubici, C., Papa,S., Dean, K. et al. (2006) Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance Oncogene 25, 6731–6748.Google Scholar
  130. 130.
    Hayakawa, M., Miyashita, H., Sakamoto, I. et al. (2003) Evidence that reactive oxygen species do not mediate NF-kappaB activation EMBO J 22, 3356–3366.Google Scholar
  131. 131.
    Arrigo, A.P. (1999) Gene expression and the thiol redox state Free Radic Biol Med 27, 936–944.Google Scholar
  132. 132.
    Nishi, T., Shimizu, N., Hiramoto, M. et al. (2002) Spatial redox regulation of a critical cysteine residue of NF-kappa B in vivo J Biol Chem 277, 44548–44556.Google Scholar
  133. 133.
    Kamata, H., Honda, S., Maeda, S. et al. (2005) Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases Cell 120, 649–661.Google Scholar
  134. 134.
    Sakon, S., Xue, X., Takekawa, M. et al. (2003) NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death EMBO J 22, 3898–3909.Google Scholar
  135. 135.
    Pham, C.G., Bubici, C., Zazzeroni, F. et al. (2004) Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species Cell 119, 529–542.Google Scholar
  136. 136.
    Chen, F., Castranova, V., Li, Z. et al. (2003) Inhibitor of nuclear factor kappaB kinase deficiency enhances oxidative stress and prolongs c-Jun NH2-terminal kinase activation induced by arsenic Cancer Res 63, 7689–7693.Google Scholar
  137. 137.
    Mattson, M.P., Goodman, Y., Luo, H. et al. (1997) Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration J Neurosci Res 49, 681–697.Google Scholar
  138. 138.
    Nakano, H., Nakajima,A., Sakon-Komazawa, S. et al. (2006) Reactive oxygen species mediate crosstalk between NF-kappaB and JNK Cell Death Differ 13, 730–737.Google Scholar
  139. 139.
    Murry, C.E., Jennings, R.B., and Reimer, K.A. (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium Circulation 74, 1124–1136.Google Scholar
  140. 140.
    Kloner, R.A. (2009) Clinical application of remote ischemic preconditioning Circulation 119, 776–778.Google Scholar
  141. 141.
    Crimi, E., Ignarro,L.J., Cacciatore, F. et al. (2009) Mechanisms by which exercise training benefits patients with heart failure Nat Rev Cardiol 6, 292–300.Google Scholar
  142. 142.
    Valen, G. (2009) Extracardiac approaches to protecting the heart Eur J Cardiothorac Surg 35, 651–657.Google Scholar
  143. 143.
    Valeur, H.S. and Valen, G. (2009) Innate immunity and myocardial adaptation to ischemia Basic Res Cardiol 104, 22–32.Google Scholar
  144. 144.
    Valen, G. (2004) Signal transduction through nuclear factor kappa B in ischemia-reperfusion and heart failure Basic Res Cardiol 99, 1–7.Google Scholar
  145. 145.
    Zhang, J., Ping, P., Vondriska, T.M. et al. (2003) Cardioprotection involves activation of NF-kappa B via PKC-dependent tyrosine and serine phosphorylation of I kappa B-alpha Am J Physiol Heart Circ Physiol 285, H1753–H1758.Google Scholar
  146. 146.
    Yang, R.C., Chen, H.W., Lu, T.S. et al. (2000) Potential protective effect of NF-kappaB activity on the polymicrobial sepsis of rats preconditioning heat shock treatment Clin Chim Acta 302, 11–22.Google Scholar
  147. 147.
    Blondeau, N., Widmann, C., Lazdunski, M. et al. (2001) Activation of the nuclear factor-kappaB is a key event in brain tolerance J Neurosci 21, 4668–4677.Google Scholar
  148. 148.
    Teoh, N., Dela,P.A., and Farrell, G. (2002) Hepatic ischemic preconditioning in mice is associated with activation of NF-kappaB, p38 kinase, and cell cycle entry Hepatology 36, 94–102.Google Scholar
  149. 149.
    Eliseev, R.A., Vanwinkle, B., Rosier, R.N. et al. (2004) Diazoxide-mediated preconditioning against apoptosis involves activation of cAMP-response element-binding protein (CREB) and NFkappaB J Biol Chem 279, 46748–46754.Google Scholar
  150. 150.
    Aleksunes, L.M., Campion, S.N., Goedken, M.J. et al. (2008) Acquired resistance to acetaminophen hepatotoxicity is associated with induction of multidrug resistance-associated protein 4 (Mrp4) in proliferating hepatocytes Toxicol Sci 104, 261–273.Google Scholar
  151. 151.
    Aleksunes, L.M., Slitt, A.L., Maher, J.M. et al. (2008) Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2 Toxicol Appl Pharmacol 226, 74–83.Google Scholar
  152. 152.
    Calabrese, E.J., Bachmann, K.A., Bailer, A.J. et al. (2007) Biological stress response terminology: Integrating the concepts of adaptive response and preconditioning stress within a hormetic dose–response framework Toxicol Appl Pharmacol 222, 122–128.Google Scholar
  153. 153.
    Gems, D. and Partridge, L. (2008) Stress-response hormesis and aging: “that which does not kill us makes us stronger” Cell Metab 7, 200–203.Google Scholar
  154. 154.
    Southam, C.M. and Ehrlich, J. (1943) Effects of extract of western red-cedar heartwood on certain wood-decaying fungi in culture Phytopathology 33, 517–524.Google Scholar
  155. 155.
    Calabrese, E.J. and Baldwin, L.A. (2002) Defining hormesis Hum Exp Toxicol 21, 91–97.Google Scholar
  156. 156.
    Mattson, M.P. (2008) Hormesis defined Ageing Res Rev 7, 1–7.Google Scholar
  157. 157.
    Calabrese, E.J. and Baldwin, L.A. (1999) The marginalization of hormesis Toxicol Pathol 27, 187–194.Google Scholar
  158. 158.
    Calabrese, E.J. and Baldwin, L.A. (2003) Toxicology rethinks its central belief Nature 421, 691–692.Google Scholar
  159. 159.
    Radak, Z., Chung,H.Y., and Goto, S. (2008) Systemic adaptation to oxidative challenge induced by regular exercise Free Radic Biol Med 44, 153–159.Google Scholar
  160. 160.
    Hayes, D.P. (2008) Adverse effects of nutritional inadequacy and excess: a hormetic model Am J Clin Nutr 88, 578S–581S.Google Scholar
  161. 161.
    Calabrese, E.J. (2005) Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses Crit Rev Toxicol 35, 463–582.Google Scholar
  162. 162.
    Hayes, D.P. (2007) Nutritional hormesis Eur J Clin Nutr 61, 147–159.Google Scholar
  163. 163.
    Son, T.G., Camandola, S., and Mattson, M.P. (2008) Hormetic dietary phytochemicals Neuromolecular Med 10, 236–246.Google Scholar
  164. 164.
    Bjelakovic, G., Nikolova, D., Ll, G. et al. (2008) Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases Cochrane Database of Systematic Reviews. Google Scholar
  165. 165.
    Lippman, S.M., Klein, E.A., Goodman, P.J. et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA 301, 39–51.Google Scholar
  166. 166.
    (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group N Engl J Med 330, 1029–1035.Google Scholar
  167. 167.
    Omenn, G.S., Goodman, G.E., Thornquist, M.D. et al. (1996) Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial J Natl Cancer Inst 88, 1550–1559.Google Scholar
  168. 168.
    Bjelakovic, G., Nikolova, D., Simonetti, R.G. et al. (2004) Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis Lancet 364, 1219–1228.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Nutrition, Institute of Basic Medical SciencesUniversity of OsloOsloNorway

Personalised recommendations